Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Rhea-AI Summary

Corvus Pharmaceuticals (Nasdaq: CRVS) will hold a conference call on March 10, 2022, at 4:30 pm ET to discuss business updates and report its Q4 and full year 2021 financial results. Investors can join the call by dialing 1-877-407-0784 for domestic or 1-201-689-8560 for international access. Registration requires the conference ID 13727689. The call will also be available via webcast, with a replay accessible on the company’s website for 90 days.

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2021 financial results.

The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) and using the conference ID 13727689. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ lead product candidate is mupadolimab (CPI-006), a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. The Company’s second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com 

FAQ

What financial results will Corvus Pharmaceuticals report on March 10, 2022?

Corvus Pharmaceuticals will report its Q4 and full year 2021 financial results during the conference call on March 10, 2022.

How can I access the Corvus Pharmaceuticals conference call?

The conference call can be accessed by dialing 1-877-407-0784 (domestic) or 1-201-689-8560 (international) using conference ID 13727689.

When will the replay of the Corvus Pharmaceuticals conference call be available?

The replay of the conference call will be available on Corvus Pharmaceuticals' website for 90 days following the event.

What is the date and time of the Corvus Pharmaceuticals conference call?

The conference call is scheduled for March 10, 2022, at 4:30 pm ET.